{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:51:08Z","timestamp":1777420268640,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Low-dose valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis post-transplant has been employed due to cost and safety. The incidence of CMV disease in CMV intermediate-risk liver recipients at 1-year after standard-dose prophylaxis is approximately 5%. However, there are limited data on outcomes after using a \u201ctrue\u201d low-dose VGC prophylaxis regimen in liver and dual-abdominal transplant recipients as VGC was not dose-adjusted in all patients with impaired renal function in prior studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective was to assess the incidence of CMV associated with low-dose VGC prophylaxis in CMV intermediate-risk liver, simultaneous pancreas-kidney (SPK), and simultaneous liver-kidney (SLK) recipients with creatinine clearance (CrCl) &gt;60 mL\/min.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective review of CMV intermediate-risk liver, SPK, and SLK recipients with CrCl &gt;60 mL\/min transplanted January 2018 to June 2022 who received VGC 450 mg daily for prophylaxis. The primary outcome was incidence of CMV infection 6-months post-transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ninety-nine transplant recipients were included (79 liver, 11 SPK, 9 SLK). The primary outcome occurred in 13% of patients (liver 10%, SPK 36%, SLK 10%), including 1 case of CMV disease and 3 breakthrough infections. In addition, 6 patients experienced CMV infection between 6-months and 1-year. Recurrence occurred in 3 patients. There was no evidence of CMV resistance. Thirty patients experienced neutropenia within 1-year, 32 were prescribed granulocyte-colony stimulating factors, and 5 experienced thrombocytopenia. Two patients died due to graft-vs-host disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Low-dose VGC prophylaxis led to comparable CMV infection rates at 6-months in CMV intermediate-risk liver and SLK recipients. However, as SPK recipients displayed higher rates of CMV infection, low-dose VGC should be avoided in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241255110","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:55:36Z","timestamp":1716796536000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5864-5133","authenticated-orcid":false,"given":"Yihan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn M.","family":"Pluckrose","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tufts Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshani","family":"Patolia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Arnouk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina","family":"Dubrovskaya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srijana","family":"Jonchhe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"bibr1-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"bibr2-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668"},{"key":"bibr3-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr306"},{"key":"bibr4-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"bibr5-10600280241255110","unstructured":"Valcyte valGCV Hydrochloride\n                      (package insert). San Francisco, CA: Genetech; 2010."},{"key":"bibr6-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2811-2815.2000"},{"key":"bibr7-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASM.0000806044.04097.fe"},{"key":"bibr8-10600280241255110","doi-asserted-by":"publisher","DOI":"10.18433\/J3805B"},{"key":"bibr9-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2018.01.023"},{"key":"bibr10-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2021.05.006"},{"key":"bibr11-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00140.x"},{"key":"bibr12-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.11.092"},{"key":"bibr13-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000251371.34968.ca"},{"key":"bibr14-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20562"},{"key":"bibr15-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13713"},{"key":"bibr16-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.09.037"},{"key":"bibr17-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13867"},{"key":"bibr18-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25047"},{"key":"bibr19-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1987"},{"key":"bibr20-10600280241255110","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12537"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241255110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241255110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241255110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:42Z","timestamp":1777374822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241255110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/10600280241255110"],"URL":"https:\/\/doi.org\/10.1177\/10600280241255110","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}